Skip to main content
DAEWOONG PHARMA logo

DAEWOONG PHARMA — Investor Relations & Filings

Ticker · 069620 ISIN · KR7069620003 KO Manufacturing
Open in API
Filings indexed 381 across all filing types
Latest filing 2023-08-10 Major Shareholding Noti…
Country KR South Korea
Listing KO 069620

About DAEWOONG PHARMA

http://crm.daewoong.co.kr/eng/main

Daewoong Pharma is an R&D-centric pharmaceutical company specializing in the development, manufacturing, and commercialization of medical products. The company's portfolio encompasses prescription drugs, with a focus on gastrointestinal and endocrine therapies, alongside biologics, healthcare products, and active pharmaceutical ingredients (APIs). A core tenet of its business model is 'Open Collaboration,' actively seeking partnerships with academic and industry entities to foster innovation. Daewoong Pharma's research efforts are directed towards breakthrough therapies, utilizing advanced drug delivery technologies and expertise in biologics. The company also offers integrated formulation and manufacturing services, supporting partners from initial development to commercial production.

Recent filings

Filing Released Lang Actions
임원ㆍ주요주주특정증권등소유상황보고서
Major Shareholding Notification Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean Financial Supervisory Service. It details the acquisition of shares by a major shareholder (Daewoong Co., Ltd.) in Daewoong Pharmaceutical. This type of filing is specifically categorized as a 'Director's Dealing' (DIRS) or 'Major Shareholding Notification' (MRQ) depending on the context. Given the focus on the major shareholder's change in ownership percentage and the specific reporting of share transactions, it aligns best with the 'Major Shareholding Notification' category.
2023-08-10 Korean
[기재정정]신규시설투자등
Regulatory Filings Classification · 100% confidence The document is a regulatory filing (DART/KRX format) regarding a correction (amendment) to a previous disclosure about a new facility investment. It details the change in the investment period due to construction delays. Since it is a specific regulatory disclosure regarding capital expenditure and investment updates that does not fit into the other specialized categories like M&A or Share Issues, it is classified as a Regulatory Filing (RNS).
2023-07-31 Korean
영업(잠정)실적(공정공시)
Earnings Release Classification · 100% confidence The document is a 'Provisional Earnings Release' (영업(잠정)실적) from Daewoong Pharmaceutical. It provides key financial highlights (revenue, operating profit, net income) for the second quarter of 2023 compared to previous periods. It is a concise summary of financial performance, which fits the definition of an Earnings Release (ER). Q2 2023
2023-07-27 Korean
주식등의대량보유상황보고서(약식)
Major Shareholding Notification Classification · 100% confidence The document is a 'Report on the Status of Large-Scale Shareholdings' (주식등의 대량보유상황보고서) filed by the National Pension Service regarding their stake in Daewoong Pharmaceutical. This is a standard regulatory filing in South Korea (often referred to as a 5% report) used to notify the market of significant changes in share ownership. Based on the provided categories, this fits the 'Major Shareholding Notification' (MRQ) classification.
2023-07-04 Korean
지속가능경영보고서등관련사항(자율공시)
Report Publication Announcement Classification · 100% confidence The document is a short regulatory filing (2,290 characters) that serves as an announcement for the publication of the company's '2023 Sustainability Report'. It explicitly states in the 'Other important matters' section that the detailed report is attached or available on the company website. According to the 'Menu vs Meal' rule, this is a Report Publication Announcement (RPA) rather than the sustainability report itself.
2023-06-29 Korean
투자판단관련주요경영사항
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from Daewoong Pharmaceutical submitted to the Korea Exchange (KRX). It details a 'Major Management Matter' regarding the application for drug approval (Fexuclue 40mg) to the Chinese National Medical Products Administration (NMPA). Since this is a specific regulatory disclosure of a material business event that does not fit into categories like financial reports, dividends, or board changes, it falls under the general regulatory filing category.
2023-06-27 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.